Freedom Softgels, a combined synergistic supplement of mixed tocotrienols (EVNol), curcumin, omega-3s, astaxanthin and other nutrients, were found to significantly reduce inflammatory marker and systolic blood pressure in healthy subjects, based on study published in Clinical Nutrition ESPEN.
The randomised, double-blinded, placebo-controlled, clinical trial was done at the Los Angeles Biomedical Research Institute at Harbor- UCLA Medical Center. A total of 80 healthy volunteers with a mean age of 48.8 ± 16 years were enrolled and randomised to receive Freedom Softgels or placebo for 4 weeks. Freedom Softgels consists of 500 mg Cavacurcumin (Wacker), 675 mg Omega 3 (450 mg EPA + 100 mg DHA + other omega 3s 125 mg), 3 mg Astaxanthin, 9.5 mg GLA, 12.5 mg mixed-tocotrienols (EVNol), 6.25 mg Hydroxy Tyrosol, Vitamin D3- 1000IU, and 12.75 mg Potassium.
The researchers concluded that reduction in systolic blood pressure and improvement of endothelial function with Freedom Softgels were likely due to its synergistic antioxidant and anti-inflammatory properties
After a short period of 4 weeks of supplementation, the study demonstrated significant reduction of systolic blood pressure in individuals who received Freedom Softgels compared to placebo. Inadequate control of systolic blood pressure rates is related to a variety of adverse cardiovascular outcomes.
In addition, the study demonstrated improvement in endothelial function in the group receiving Freedom Softgels, measured by brachial flow-mediated dilatation (bFMD). This measurement reflects changes in the brachial artery diameter after regional ischemia. The group receiving Freedom Softgels also showed significant decrease of inflammatory biomarkers IL-6 and hsCRP.
In healthy individuals, high levels of circulatory IL-6 is linked to increased risk of development and progression of ischemic heart disease. This finding suggests that Freedom Softgels could help in reducing inflammation and improving endothelial reactivity over a 4 weeks.
The researchers concluded that reduction in systolic blood pressure and improvement of endothelial function with Freedom Softgels were likely due to its synergistic antioxidant and anti-inflammatory properties and has the potential to be used to complement antihypertensive therapies.
“Tocotrienol (EVNol) possess diverse unique biological activities like antioxidant, anti-inflammatory and anti-aging properties. This synergistic combo of antioxidants and cardio-protective ingredients like curcumin, EPA, astaxanthin, Tocotrienol (EVNol) and other nutrients, helps promote healthy cardiovascular function and other health benefits (such as better immune response) via its superior antioxidant and anti-inflammatory functions,” said Bryan See, Business Development Manager of ExcelVite.
Dr Raj Chopra, CEO of Tishcon said: “Dietary supplements have received considerable interest due to potential nutritional, safety and therapeutic effects. This trial validates that Freedom softgels containing Cavacurcumin, Omega 3, Astaxanthin, GLA, with Vitamin D, EVNol and hydroxytyrosol exhibits anti-inflammatory and antioxidant properties. Such observations highlight the importance and growing need for accessible and effective anti- inflammatory and anti-hypertensive interventions”.